Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
Stocks · News reference
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne
BIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.